March 10, 2020 — In the years to come, public data will play an increasingly important role in drug discovery and development.
In this brief, learn how biotechs are strategically using publicly available data to:
- Accelerate their path to the clinic by circumventing time-consuming, expensive data generation
- Increase the likelihood of success by mitigating the reproducibility risks inherent in preclinical models
- Quickly incorporate data-driven evidence to guide critical decisions related to indication matching, patient stratification, and MOA investigation
- Build data assets that support their eventual regulatory filings